MedicaNatumin develops, manufactures and markets health and beauty products based on innovative ingredients and research. The company’s patented platforms were developed by its own research group in collaboration with Karolinska Institute and Sahlgrenska Academy. Its leading brands of food supplements, medical devices, and dermatological and cosmetic products are widely sold in the Nordic market, and to consumers around the world. Its sales channels are specialty retail, department stores, pharmacies and e-commerce. Outside the Nordics, MedicaNatumin uses distributors. The group targets SEK 200m in sales for 2020.
We believe that MedicaNatumin will benefit from the solid underlying market growth on the OTC market and develop products in several different indications. By investing more in its commercial infrastructure and continuing to build clinical evidence, we see opportunities for MedicaNatumin to continue to deliver high sales growth and launch Jabushe and other products in new markets.
We note a number of risk factors for MedicaNatumin, including market risk, partnership risk, competition, legal and regulatory risk, product development risk and currency and macroeconomic risk. From a short-term perspective, there is a risk of a destocking effect in China related to large Jabushe orders.